3400 One First Canadian Place
Toronto, ON M5X 1A4
Full Time Employees:
|Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA||Chairman & CFO||60k||N/A||1973|
|Dr. Yuval Avnir Ph.D.||Head of R&D and Interim CEO||N/A||N/A||N/A|
|Dr. Riva Kovjazin M.D.||Sr. Scientist & Member of Scientific Advisory Board||N/A||N/A||N/A|
Vaxil Bio Ltd., an immunotherapy biotech company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Vaxil Bio Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.